TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03474081
Drug: Placebo to match FF/UMEC/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching FF/UMEC/VI will be available as a dry white powder of lactose or magnesium stearate, administered via ELLIPTA DPI.
Study: NCT02437786
Drug: GRAZAX
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRAZAX
Study: NCT00272116
Drug: Zinc and vitamin A single dose at enrollment
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children
Study: NCT00737594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules for oral administration
Study: NCT01730404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02558400
Drug: PG324 Ophthalmic Solution 0.02%/0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)
Study: NCT04507165
Drug: opioid free anesthesia
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia induction: Dexmedetomidine 1µg/kg (intravenous infusion within 10min), propofol 1.5-2mg/kg (intravenous bolus), lidocaine 1.5-2mg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus), and 0.5% tetracaine 5ml for surface anesthesia of the throat.~Maintenance of anesthesia: Continuous infusion of propofol and dexmedetomidine \[0.4μg/(kg.h)\]. The infusion rate of propofol was adjusted according to bispectral index value. Cisatracurium besylate was given as needed. Flurbiprofen 50mg was given intravenously before the skin incision and suture respectively.~Remedy: If blood pressure rises (more than 30% of the mean arterial pressure after induction), and heart rate increases (more than 30% of heart rate after induction) during skin incision, lidocaine 1.5mg/kg will be given intravenously and then be continuously infused at a rate of 1.5mg/(kg.h).
Study: NCT04507165
Drug: opioid based anesthesia
Normalized name: Opioid anesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia induction: Propofol 1.5-2mg/kg (intravenous bolus), sufentanil 0.3μg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus).~Maintenance of anesthesia: Continuous infusion of propofol and remifentanil. The infusion rate of propofol was adjusted according to BIS value. The infusion rate of remifentanil was 0.1-0.5µg/(kg.min) and adjusted according to the change of heart rate and blood pressure. Cisatracurium besylate was given as needed. Sufentanil 0.1μg/kg and flurbiprofen 50mg were given intravenously before the skin incision and suture respectively.
Study: NCT00911573
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg IV every 12 hours up to 14 days
Study: NCT00911573
Drug: Clindamycin (or Vancomycin if needed)
Normalized name: clindamycin Medicated Pad or Tape
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For clindamycin 10mg/kg (not to exceed 900mg) IV every 8 hours up to 14 days. For vancomycin 15mg/kg (not to exceed 2g/day and adjusted as needed for renal impairment) IV every 8 hours
Study: NCT03159104
Drug: Tenoten for children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use.
Study: NCT03159104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use.
Study: NCT01076621
Drug: 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data collection of the use of 0.5 mg estradiol and 0.1 mg norethisterone acetate (NETA) in women in connection to a daily clinical practice.
Study: NCT02530996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the experimental days, patients reported to the laboratory after having consumed a standardized breakfast and oral BH4 (10mg/kg) or placebo five hours prior to their arrival. All measurements were taken at the same time of day to eliminate any diurnal effects. All participants abstained from alcohol, caffeine, and exercise for ≥12 hours prior to the study. Additionally, vasodilatory medications were discontinued 12 hours prior to study visit. In premenopausal women, measurements were performed during the early follicular phase of the menstrual cycle. All measurements were made under quiet, comfortable, ambient (\~22°C) laboratory conditions.
Study: NCT02048371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 days on and 7 days off
Study: NCT02380898
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg ketorolac immediately before induction of anesthesia
Study: NCT02380898
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL normal saline 0.9% immediately before induction of anesthesia
Study: NCT02967939
Drug: Viread®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viread® 300mg tablet qd + placebo tablet matching to DA-2802 319mg.
Study: NCT04030247
Drug: Plant Sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a plant sterol supplement to take twice daily from their cardiologist/dietician in management of their moderate risk of cardiovascular disease.
Study: NCT02234921
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single dose of cyclophosphamide, 300 mg/m2, will be administered intravenously 3 Days prior to the first vaccine.
Study: NCT00240110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm
Study: NCT03468972
Drug: Immunosuppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: At 3 months after randomization, patients in the corticosteroid arm who have persistent proteinuria of ≥ 1.0 g/g creatinine, or fast decline in eGFR ≥ 15% from the baseline value, will additionally receive cyclosphosphamide during the following 3 months. Patients who have substantial decreased amount of proteinuria \< 1.0 g/g creatinine at 3 months will continue protocol-based corticosteroids during the same period. At 6 months after randomization, patients who receive add-on cyclophosphamide will switch to azathioprine as a maintenance therapy and those who receive corticosteroids alone will discontinue the treatment and will be followed up during 24 months thereafter. Assessment of outcome will be done at 6 months and at 36 months.
Study: NCT01722292
Drug: LY2940680
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01722292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01417364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected IM weekly throughout study
Study: NCT00001724
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00411190
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen will be administered orally
Study: NCT00411190
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen will be administered orally
Study: NCT02239146
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
Study: NCT02161276
Drug: TNTL capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were asked to taken drugs 3 times a day, with each time 3 grains
Study: NCT02161276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were asked to taken drugs 3 times a day, with each time 3 grains
Study: NCT01013415
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02270723
Drug: 5% Human Albumin  Behring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 5% Human Albumin during major surgery
Study: NCT01151761
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2, PO
Study: NCT01151761
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2
Study: NCT02333890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02406443
Drug: Sitaglitpin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days
Study: NCT01181024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)
Study: NCT04953871
Drug: TNF Inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitors are widely used in patients with spondyloarthritis
Study: NCT01181024
Drug: RO5303253
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts receiving single ascending doses
Study: NCT01181024
Drug: RO5303253
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT01181024
Drug: RO5303253
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses
Study: NCT01131741
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group receives 3 mL of 1% lidocaine containing epinephrine IV during operation.
Study: NCT00403780
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule placebo once or twice daily up to a total dose of 8 capsules(4 capsules twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
Study: NCT03689075
Drug: Envarsus Oral Product
Normalized name: Envarsus Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation
Study: NCT03631277
Drug: Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium hydroxide( Dycal ® Dentsply Caulk )was applied using calcium hydroxide applicator followed by glass ionomer and then composite resin as a final restoration
Study: NCT04142151
Drug: Sanchitongshu
Approvals — FDA: no, EMA: no, PMDA: no
Description: SanchiTongshu capsule produced by Chengdu Huashen Group Co., Ltd.
Study: NCT04142151
Drug: placebo of Sanchitongshu
Approvals — FDA: no, EMA: no, PMDA: no
Description: SanchiTongshu palcebo capsule contained dark brown muscovada sugar and the same inactive excipient (starch). Produced by Chengdu Huashen Group Co., Ltd.
Study: NCT00913393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV every 2 weeks for 22 weeks
Study: NCT03037541
Drug: Placebo Cetaphil cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Cetaphil Cream will be used once daily for seven consecutive days
Study: NCT00003358
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02603445
Drug: BCL201
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01407796
Drug: Endotoxin (E. coli O:113, Reference Endotoxin)
Normalized name: E.COLI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01407796
Drug: [18F](+/-)NOS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01685983
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
Study: NCT00364533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Dose Matching placebo for 3 days
Study: NCT00331227
Drug: Isotonix OPC-3 (flavonoid supplement)
Normalized name: naphazoline hydrochloride 0.27 MG/ML / pheniramine maleate 3.15 MG/ML [Opcon-A]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01394887
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 850 mg gel capsules with starch (6.8 calories)as placebo
Study: NCT03123614
Drug: Prednisolone Acetate 1% Oph Susp
Normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04109833
Drug: ABT
Normalized name: Abtrim
Approvals — FDA: no, EMA: no, PMDA: no
Description: any antibiotic therapy in the first week of life
Study: NCT03947970
Drug: [14C] CR845
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose of 230 mcg CR845 solution containing 100 microcuries \[14C\] CR845, administered via IV bolus (the total dose of CR845 will range from 1.7 to 3.1 mcg/kg)
Study: NCT00973102
Drug: Premarin IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time dose of Premarin IV
Study: NCT00973102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time dose of placebo.
Study: NCT03378648
Drug: CHF6366
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: CHF6366 (Part 1 - SAD) Single doses of CHF6366 at each period (for up to 3 periods per subject)~Drug: CHF6366 (Part 2 - MAD) Once daily doses of CHF6366 for 7 days~Drug: CHF6366 (Part 3) Single dose of CHF6366
Study: NCT03378648
Drug: Placebo CHF6366
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo (Part 1 - SAD) Single doses of placebo matching CHF6366 at each period (for up to 3 periods per subjects)~Drug: Placebo (Part 2 - MAD) Once daily dose of placebo matching CHF6366 for 7 days~Drug: Placebo (Part 3) Single dose of placebo matching CHF6366
Study: NCT00272688
Drug: Levodopa (drug), intraduodenal administration
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00944463
Drug: Gemcitabine+simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and simvastatin
Study: NCT03926962
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visually matching placebo
Study: NCT01439126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, or 0.3 mg at Week 11; KAPVAY™ 0.1 mg, KAPVAY™ 0.2 mg, or placebo at Week 12; KAPVAY™ 0.1 mg or placebo at Week 13; placebo from Weeks 14-36
Study: NCT03715192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01290900
Drug: NXL104
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Solution
Study: NCT01290900
Drug: Placebo Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Saline
Study: NCT04129710
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
Study: NCT04129710
Drug: PEGylated recombinant human granulocyte colony
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
Study: NCT02244151
Drug: Decapeptyl® diario
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.
Study: NCT02244151
Drug: Decapeptyl® daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decapeptyl® daily OPU 36 hrs after GnRH administration
Study: NCT00624416
Drug: Prednisolone synthetic cortisone and Isoproterenol together
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
Study: NCT00490022
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel for one month
Study: NCT04615325
Drug: RO7303359
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO730359 will be administered as a single intravitreal injection.
Study: NCT01638104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once by 12 hour continuous intravenous infusion with D5W (USP)
Study: NCT01869413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
Study: NCT01355796
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 7 % saline aerosolized twice a day for 2 weeks
Study: NCT02871687
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20 mg daily followed by potential increase to 40 mg simvastatin according to dose escalation procedure
Study: NCT02871687
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin 40 mg daily followed by potential increase to 80 mg pravastatin according to dose escalation procedure
Study: NCT02973776
Drug: Dermoval®/Dermovate®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03447093
Drug: Propylthiouracil Pill
Normalized name: propylthiouracil Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who developed GD received propylthiouracil treatment
Study: NCT01522404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group
Study: NCT05840692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00287794
Drug: diazepam, melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of diazepam or such drugs may improve the sleep disturbance of patients with RA.
Study: NCT02315508
Drug: AUT00063
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg orally, once a day, for 4 weeks
Study: NCT02315508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, once a day, for 4 weeks
Study: NCT01669408
Drug: Cold crystalloid infusions, 0.9%NaCl or Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
Study: NCT02012088
Drug: RCOMP
Normalized name: Sarcomphalus joazeiro bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
Study: NCT01479946
Drug: Electrochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: bleomycin together with electroporation
Study: NCT01495520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: os, pill, b.i.d., 30 days
Study: NCT00513955
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00513955
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00513955
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02794389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02177513
Drug: Placebo + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
Study: NCT02177513
Drug: 6.9% cannabis oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will consume a brownie containing the equivalent of one active (6.91% THC) cannabis cigarette.
Study: NCT00739466
Drug: Saline infusion (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
Study: NCT01930552
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:Solution for infusion Route of administration: Intravenous
Study: NCT00539929
Drug: E6201 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00539929
Drug: E6201 0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00539929
Drug: E6201 0.03%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00539929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02204852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01669213
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: before 5 minutes spinal anesthesia, injection of normal saline 5 ml
Study: NCT02064608
Drug: AZD2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR inhibitor
Study: NCT01071616
Drug: Cannabis Cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02643823
Drug: DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated by conventional drugs (DMARDs) for alleviating disease.
Study: NCT02666794
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mcg
Study: NCT02666794
Drug: Intrathecal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mcg
Study: NCT02155530
Drug: pravastatin 20 mg
Normalized name: pravastatin 20 mg oral tablet
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
Study: NCT00261742
Drug: Penicillin versus cefuroxim per os
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01638559
Drug: Immunosuppression withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
Study: NCT00686556
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg
Study: NCT04689971
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin, pregabalin, or amitriptyline